Birdwatch Note
2023-05-02 03:52:53 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
Once a drug has been approved for human use, doctors are generally able to prescribe it for any illness. https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label Ivermectin has been approved for human use. https://www.covid19treatmentguidelines.nih.gov/therapies/miscellaneous-drugs/ivermectin/#:~:text=Ivermectin%20is%20a%20Food%20and,onchocerciasis%2C%20helminthiases%2C%20and%20scabies.&text=For%20these%20indications%2C%20ivermectin%20has,and%20is%20generally%20well%20tolerated.
Written by 1EA7258A808A801310485B6323639526180910D8D193D752AA620CCE313DBB88
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1429050070243192839
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1653246153972916227
- noteId - 1653246153972916227
- participantId -
- noteAuthorParticipantId - 1EA7258A808A801310485B6323639526180910D8D193D752AA620CCE313DBB88 Participant Details
- createdAtMillis - 1682999573590
- tweetId - 1429050070243192839
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Once a drug has been approved for human use, doctors are generally able to prescribe it for any illness. https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label Ivermectin has been approved for human use. https://www.covid19treatmentguidelines.nih.gov/therapies/miscellaneous-drugs/ivermectin/#:~:text=Ivermectin%20is%20a%20Food%20and,onchocerciasis%2C%20helminthiases%2C%20and%20scabies.&text=For%20these%20indications%2C%20ivermectin%20has,and%20is%20generally%20well%20tolerated.
Note Status History
createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
2023-05-02 03:52:53 UTC (1682999573590) |
1969-12-31 23:59:59 UTC (-1) |
2023-05-06 02:42:24 UTC (1683340944665) |
NEEDS_MORE_RATINGS | 1969-12-31 23:59:59 UTC (-1) |
Note Ratings
rated at | rated by | |
2023-05-03 08:29:36 -0500 | Rating Details | |
2023-05-03 08:02:34 -0500 | Rating Details | |
2023-05-03 07:03:15 -0500 | Rating Details | |
2023-05-02 17:53:36 -0500 | Rating Details | |
2023-05-02 16:15:53 -0500 | Rating Details | |
2023-05-02 14:56:03 -0500 | Rating Details | |
2023-05-02 14:50:55 -0500 | Rating Details | |
2023-05-02 14:03:49 -0500 | Rating Details | |
2023-05-02 13:53:10 -0500 | Rating Details | |
2023-05-02 12:48:06 -0500 | Rating Details | |
2023-05-02 12:45:57 -0500 | Rating Details | |
2023-05-02 12:35:22 -0500 | Rating Details | |
2023-05-02 12:00:55 -0500 | Rating Details | |
2023-05-02 11:52:38 -0500 | Rating Details | |
2023-05-02 11:25:16 -0500 | Rating Details | |
2023-05-02 11:16:07 -0500 | Rating Details | |
2023-05-02 11:06:08 -0500 | Rating Details | |
2023-05-02 11:02:52 -0500 | Rating Details | |
2023-05-02 10:50:48 -0500 | Rating Details | |
2023-05-02 10:43:59 -0500 | Rating Details | |
2023-05-02 10:41:57 -0500 | Rating Details | |
2023-05-02 10:40:05 -0500 | Rating Details | |
2023-05-02 10:30:17 -0500 | Rating Details | |
2023-05-02 09:47:09 -0500 | Rating Details | |
2023-05-02 08:58:10 -0500 | Rating Details | |
2023-05-02 08:01:08 -0500 | Rating Details | |
2023-05-02 07:37:02 -0500 | Rating Details | |
2023-05-02 07:36:27 -0500 | Rating Details | |
2023-05-02 07:04:53 -0500 | Rating Details | |
2023-05-02 06:30:53 -0500 | Rating Details | |
2023-05-02 06:29:59 -0500 | Rating Details | |
2023-05-02 05:13:16 -0500 | Rating Details | |
2023-05-02 04:41:49 -0500 | Rating Details | |
2023-05-02 04:33:11 -0500 | Rating Details | |
2023-05-02 04:31:48 -0500 | Rating Details | |
2023-05-02 04:24:48 -0500 | Rating Details | |
2023-05-02 03:58:20 -0500 | Rating Details | |
2023-05-02 03:44:06 -0500 | Rating Details | |
2023-05-02 03:43:10 -0500 | Rating Details | |
2023-05-02 03:41:29 -0500 | Rating Details | |
2023-05-02 03:39:11 -0500 | Rating Details | |
2023-05-02 03:37:18 -0500 | Rating Details | |
2023-05-02 03:31:37 -0500 | Rating Details | |
2023-05-02 03:24:44 -0500 | Rating Details | |
2023-05-02 03:05:41 -0500 | Rating Details | |
2023-05-02 02:51:06 -0500 | Rating Details | |
2023-05-02 02:32:32 -0500 | Rating Details | |
2023-05-02 02:11:26 -0500 | Rating Details | |
2023-05-02 01:53:04 -0500 | Rating Details | |
2023-05-02 01:45:27 -0500 | Rating Details | |
2023-05-01 23:12:24 -0500 | Rating Details | |
2023-05-01 23:09:46 -0500 | Rating Details | |
2023-05-17 22:08:15 -0500 | Rating Details | |
2023-05-17 21:38:52 -0500 | Rating Details | |
2023-05-17 22:08:15 -0500 | Rating Details | |
2023-05-02 14:56:03 -0500 | Rating Details | |
2023-05-02 10:30:17 -0500 | Rating Details | |
2023-05-02 03:41:29 -0500 | Rating Details | |
2023-05-02 03:58:20 -0500 | Rating Details | |
2023-05-02 03:05:41 -0500 | Rating Details | |
2023-05-01 23:09:46 -0500 | Rating Details | |
2023-05-02 12:35:22 -0500 | Rating Details | |
2023-05-02 03:44:06 -0500 | Rating Details | |
2023-05-03 08:29:36 -0500 | Rating Details | |
2023-05-02 14:50:55 -0500 | Rating Details | |
2023-05-02 12:48:06 -0500 | Rating Details | |
2023-05-02 16:15:53 -0500 | Rating Details | |
2023-05-02 04:41:49 -0500 | Rating Details | |
2023-05-02 10:50:48 -0500 | Rating Details | |
2023-05-02 02:51:06 -0500 | Rating Details | |
2023-05-02 03:39:11 -0500 | Rating Details | |
2023-05-02 10:41:57 -0500 | Rating Details | |
2023-05-17 21:38:52 -0500 | Rating Details | |
2023-05-02 01:45:27 -0500 | Rating Details | |
2023-05-02 05:13:16 -0500 | Rating Details | |
2023-05-02 06:30:53 -0500 | Rating Details | |
2023-05-02 11:25:16 -0500 | Rating Details | |
2023-05-02 07:04:53 -0500 | Rating Details | |
2023-05-02 02:32:32 -0500 | Rating Details | |
2023-05-02 13:53:10 -0500 | Rating Details | |
2023-05-02 03:43:10 -0500 | Rating Details | |
2023-05-02 04:31:48 -0500 | Rating Details | |
2023-05-02 10:43:59 -0500 | Rating Details | |
2023-05-02 06:29:59 -0500 | Rating Details | |
2023-05-01 23:12:24 -0500 | Rating Details | |
2023-05-02 01:53:04 -0500 | Rating Details | |
2023-05-02 11:16:07 -0500 | Rating Details | |
2023-05-02 12:00:55 -0500 | Rating Details | |
2023-05-02 07:37:02 -0500 | Rating Details | |
2023-05-03 08:02:34 -0500 | Rating Details | |
2023-05-02 08:01:08 -0500 | Rating Details | |
2023-05-02 10:40:05 -0500 | Rating Details | |
2023-05-02 07:36:27 -0500 | Rating Details | |
2023-05-02 08:58:10 -0500 | Rating Details | |
2023-05-02 04:24:48 -0500 | Rating Details | |
2023-05-02 12:45:57 -0500 | Rating Details | |
2023-05-02 17:53:36 -0500 | Rating Details | |
2023-05-03 07:03:15 -0500 | Rating Details | |
2023-05-02 04:33:11 -0500 | Rating Details | |
2023-05-02 03:37:18 -0500 | Rating Details | |
2023-05-02 11:52:38 -0500 | Rating Details | |
2023-05-02 11:02:52 -0500 | Rating Details | |
2023-05-02 03:31:37 -0500 | Rating Details | |
2023-05-02 03:24:44 -0500 | Rating Details | |
2023-05-02 11:06:08 -0500 | Rating Details | |
2023-05-02 14:03:49 -0500 | Rating Details | |
2023-05-02 09:47:09 -0500 | Rating Details | |
2023-05-02 02:11:26 -0500 | Rating Details | |
2023-05-22 09:30:19 -0500 | Rating Details | |
2023-05-22 18:19:10 -0500 | Rating Details | |
2023-06-08 09:43:32 -0500 | Rating Details | |
2023-06-25 08:40:51 -0500 | Rating Details | |
2023-07-26 10:31:56 -0500 | Rating Details | |
2023-08-11 18:11:50 -0500 | Rating Details | |
2023-08-11 14:40:14 -0500 | Rating Details | |
2023-08-11 09:27:03 -0500 | Rating Details | |
2023-08-11 09:24:35 -0500 | Rating Details | |
2023-08-11 06:56:26 -0500 | Rating Details | |
2023-08-13 16:15:30 -0500 | Rating Details | |
2023-08-13 12:38:59 -0500 | Rating Details | |
2023-08-13 10:58:07 -0500 | Rating Details | |
2023-08-13 07:16:49 -0500 | Rating Details | |
2023-08-13 06:39:42 -0500 | Rating Details | |
2023-08-13 04:29:00 -0500 | Rating Details | |
2023-08-13 03:08:22 -0500 | Rating Details | |
2023-08-12 23:15:58 -0500 | Rating Details | |
2023-08-12 21:00:56 -0500 | Rating Details | |
2023-08-12 20:11:18 -0500 | Rating Details | |
2023-08-12 19:48:11 -0500 | Rating Details | |
2023-08-12 18:56:09 -0500 | Rating Details | |
2023-08-12 16:32:17 -0500 | Rating Details | |
2023-08-12 16:24:25 -0500 | Rating Details | |
2023-08-12 13:48:38 -0500 | Rating Details | |
2023-08-12 08:27:52 -0500 | Rating Details | |
2023-08-12 07:03:50 -0500 | Rating Details | |
2023-08-13 22:34:23 -0500 | Rating Details | |
2023-08-15 12:29:22 -0500 | Rating Details | |
2023-08-15 12:14:23 -0500 | Rating Details | |
2023-08-15 11:35:35 -0500 | Rating Details | |
2023-08-15 09:53:44 -0500 | Rating Details | |
2023-08-16 17:58:09 -0500 | Rating Details | |
2023-08-16 13:23:45 -0500 | Rating Details | |
2023-08-17 16:28:32 -0500 | Rating Details | |
2023-08-14 22:00:12 -0500 | Rating Details | |
2023-08-13 11:08:07 -0500 | Rating Details | |
2023-08-13 08:34:52 -0500 | Rating Details | |
2023-08-13 07:41:36 -0500 | Rating Details | |
2023-08-13 07:34:27 -0500 | Rating Details | |
2023-08-12 22:58:36 -0500 | Rating Details | |
2023-08-12 18:57:57 -0500 | Rating Details | |
2023-08-12 15:25:03 -0500 | Rating Details | |
2023-08-12 09:17:30 -0500 | Rating Details | |
2023-08-12 08:16:00 -0500 | Rating Details | |
2023-08-26 12:44:41 -0500 | Rating Details | |
2023-12-03 20:09:49 -0600 | Rating Details | |
2023-12-18 23:26:58 -0600 | Rating Details | |
2024-02-01 15:32:41 -0600 | Rating Details | |
2024-02-11 08:52:23 -0600 | Rating Details | |
2024-03-08 17:32:41 -0600 | Rating Details | |
2024-03-09 19:53:53 -0600 | Rating Details | |
2024-03-22 21:25:40 -0500 | Rating Details | |
2024-03-22 20:50:55 -0500 | Rating Details | |
2024-03-22 19:27:54 -0500 | Rating Details | |
2024-03-22 17:34:36 -0500 | Rating Details | |
2024-03-22 15:24:18 -0500 | Rating Details | |
2024-03-22 13:08:15 -0500 | Rating Details | |
2024-03-22 12:48:13 -0500 | Rating Details | |
2024-03-22 10:22:32 -0500 | Rating Details | |
2024-03-22 08:31:34 -0500 | Rating Details | |
2024-03-23 18:17:22 -0500 | Rating Details | |
2024-03-23 07:52:55 -0500 | Rating Details | |
2024-03-23 02:57:09 -0500 | Rating Details | |
2024-03-23 02:33:27 -0500 | Rating Details | |
2024-03-23 00:53:42 -0500 | Rating Details | |
2024-03-22 22:33:26 -0500 | Rating Details | |
2024-03-23 21:33:24 -0500 | Rating Details | |
2024-03-23 16:58:14 -0500 | Rating Details | |
2024-03-23 14:44:29 -0500 | Rating Details | |
2024-03-23 08:30:30 -0500 | Rating Details | |
2024-03-23 05:25:59 -0500 | Rating Details | |
2024-03-23 02:25:45 -0500 | Rating Details | |
2024-03-23 01:49:43 -0500 | Rating Details | |
2024-03-22 21:14:41 -0500 | Rating Details | |
2024-03-22 20:33:45 -0500 | Rating Details | |
2024-03-22 19:08:19 -0500 | Rating Details | |
2024-03-22 17:58:51 -0500 | Rating Details | |
2024-03-22 17:43:49 -0500 | Rating Details | |
2024-03-22 14:19:58 -0500 | Rating Details | |
2024-03-22 13:57:34 -0500 | Rating Details | |
2024-03-22 12:37:01 -0500 | Rating Details | |
2024-03-22 08:22:07 -0500 | Rating Details | |
2024-03-22 07:01:51 -0500 | Rating Details | |
2024-03-14 08:14:10 -0500 | Rating Details | |
2024-03-11 18:17:09 -0500 | Rating Details | |
2024-03-23 06:39:28 -0500 | Rating Details | |
2024-03-23 05:34:40 -0500 | Rating Details | |
2024-03-22 20:10:47 -0500 | Rating Details | |
2024-03-22 19:37:46 -0500 | Rating Details | |
2024-03-22 18:26:02 -0500 | Rating Details | |
2024-03-22 17:54:37 -0500 | Rating Details | |
2024-03-22 15:18:51 -0500 | Rating Details | |
2024-03-22 13:33:34 -0500 | Rating Details | |
2024-03-22 12:02:57 -0500 | Rating Details | |
2024-03-22 07:30:46 -0500 | Rating Details | |
2024-03-22 02:35:27 -0500 | Rating Details | |
2024-03-22 01:48:30 -0500 | Rating Details | |
2024-03-22 01:48:11 -0500 | Rating Details | |
2024-03-31 20:11:05 -0500 | Rating Details | |
2024-03-31 17:03:32 -0500 | Rating Details | |
2024-03-31 16:36:09 -0500 | Rating Details | |
2024-04-02 02:06:24 -0500 | Rating Details | |
2024-04-01 16:12:44 -0500 | Rating Details | |
2024-04-01 11:28:48 -0500 | Rating Details | |
2024-04-01 02:07:22 -0500 | Rating Details | |
2024-03-31 22:57:23 -0500 | Rating Details |